PF-610355

PF-610355
Clinical data
Routes of; administration	Inhalation
ATC code	None;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name N-[(4'-Hydroxy-3-biphenylyl)methyl]-2-[3-(2-{[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]acetamide;
CAS Number	862541-45-5;
PubChem CID	11505444;
ChemSpider	9680243 ;
UNII	ZH5SMU97AJ;
ChEMBL	ChEMBL1240967 ;
CompTox Dashboard (EPA)	DTXSID501099960 ;
Chemical and physical data
Formula	C34H39N3O6S
Molar mass	617.76 g·mol−1

PF-610355 (also known as PF-00610355 or PF-610,355) is an inhalable^[1] ultra-long-acting β₂ adrenoreceptor agonist^[2] (ultra-LABA) that was investigated as a treatment of asthma and COPD by Pfizer.^[3] It utilizes a sulfonamide agonist headgroup, that confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties minimized systemic exposure following inhalation and reduced systemically-mediated adverse events.^[4] Its in vivo duration on action confirmed its potential for once-daily use in humans. ^[5]

The investigation and development of PF-610355 were discontinued in 2011,^[6] likely for strategic and regulatory reasons.^[7]

References

^ Diderichsen PM, Cox E, Martin SW, Cleton A, Ribbing J (November 2013). "Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease". British Journal of Clinical Pharmacology. 76 (5): 752–62. doi:10.1111/bcp.12080. PMC 3853534. PMID 23323609.
^ Cazzola M, Calzetta L, Matera MG (May 2011). "β(2) -adrenoceptor agonists: current and future direction". British Journal of Pharmacology. 163 (1): 4–17. doi:10.1111/j.1476-5381.2011.01216.x. PMC 3085864. PMID 21232045.
^ "Pfizer Pipeline as of January 27, 2010" (PDF). Pfizer Inc. p. 6. Retrieved 9 April 2016.
^ Glossop PA, Lane CA, Price DA, Bunnage ME, Lewthwaite RA, James K, et al. (September 2010). "Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup". Journal of Medicinal Chemistry. 53 (18): 6640–52. doi:10.1021/jm1005989. PMID 20804199.
^ Acton QA, ed. (2012-01-09). Issues in Medical Chemistry Edition. ScholarlyEditions. ISBN 978-1-464-96440-4.
^ "AdisInsight: PF 610355". Springer International Publishing AG. Retrieved 25 March 2016.
^ Cazzola M, Page CP, Rogliani P, Matera MG (April 2013). "β2-agonist therapy in lung disease". American Journal of Respiratory and Critical Care Medicine. 187 (7): 690–6. doi:10.1164/rccm.201209-1739PP. PMID 23348973.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[1] Diderichsen PM, Cox E, Martin SW, Cleton A, Ribbing J (November 2013). "Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease". British Journal of Clinical Pharmacology. 76 (5): 752–62. doi:10.1111/bcp.12080. PMC 3853534. PMID 23323609.

[Cazzola-2] Cazzola M, Calzetta L, Matera MG (May 2011). "β(2) -adrenoceptor agonists: current and future direction". British Journal of Pharmacology. 163 (1): 4–17. doi:10.1111/j.1476-5381.2011.01216.x. PMC 3085864. PMID 21232045.

[3] "Pfizer Pipeline as of January 27, 2010" (PDF). Pfizer Inc. p. 6. Retrieved 9 April 2016.

[4] Glossop PA, Lane CA, Price DA, Bunnage ME, Lewthwaite RA, James K, et al. (September 2010). "Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup". Journal of Medicinal Chemistry. 53 (18): 6640–52. doi:10.1021/jm1005989. PMID 20804199.

[5] Acton QA, ed. (2012-01-09). Issues in Medical Chemistry Edition. ScholarlyEditions. ISBN 978-1-464-96440-4.

[6] "AdisInsight: PF 610355". Springer International Publishing AG. Retrieved 25 March 2016.

[7] Cazzola M, Page CP, Rogliani P, Matera MG (April 2013). "β2-agonist therapy in lung disease". American Journal of Respiratory and Critical Care Medicine. 187 (7): 690–6. doi:10.1164/rccm.201209-1739PP. PMID 23348973.

[1]

[2]

[3]

[4]

[5]

[6]

[7]